Literature DB >> 11035424

Parvovirus B19 infection associated with the production of anti-neutrophil cytoplasmic antibody (ANCA) and anticardiolipin antibody (aCL).

T N Chou1, T C Hsu, R M Chen, L I Lin, G J Tsay.   

Abstract

We described four patients who had clinical diagnosis of erythema infectiosum and presented with skin rash, polyarthralgia, polyarthritis, and mild fever. Anti-parvovirus B19 IgM and IgG antibodies were found in all four patients and parvovirus B19 DNA was detected in three of the four patients by polymerase chain reaction (PCR) in sera using standard methods. Anticardiolipin antibody (aCL) was positive in three of the four patients included three with anti-beta2 glycoprotein I (beta2GPI). The immunoglobulin isotype of aCL was found to be IgM. Anti-neutrophil cytoplasmic antibody (ANCA) included three p-ANCA and one c-ANCA was detected in all four patients by indirect immunofluoresence (IIF). Both anti-proteinase 3 (PR3) and anti-myeloperoxidase (MPO) antibodies were found in two patients whom had polyarthritis for more than 6 months. These data indicate parvovirus B19 may be linked to the induction of an autoimmune response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035424     DOI: 10.1177/096120330000900714

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  Infective endocarditis mimics ANCA associated glomerulonephritis.

Authors:  Mohammad Reza Ardalan; Matias Trillini
Journal:  Caspian J Intern Med       Date:  2012

2.  Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge.

Authors:  Branka Bonaci-Nikolic; Sladjana Andrejevic; Milorad Pavlovic; Zoran Dimcic; Branislava Ivanovic; Milos Nikolic
Journal:  Clin Rheumatol       Date:  2010-03-20       Impact factor: 2.980

Review 3.  Serum ANCA as Disease Biomarkers: Clinical Implications Beyond Vasculitis.

Authors:  Marco Folci; Giacomo Ramponi; Virginia Solitano; Enrico Brunetta
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-30       Impact factor: 10.817

4.  Human parvovirus B19 nonstructural protein NS1 enhanced the expression of cleavage of 70 kDa U1-snRNP autoantigen.

Authors:  Bor-Show Tzang; Der-Yuan Chen; Chun-Chou Tsai; Szu-Yi Chiang; Tsung-Ming Lin; Tsai-Ching Hsu
Journal:  J Biomed Sci       Date:  2010-05-25       Impact factor: 8.410

Review 5.  Systematic review of case reports of antiphospholipid syndrome following infection.

Authors:  N Abdel-Wahab; M A Lopez-Olivo; G P Pinto-Patarroyo; M E Suarez-Almazor
Journal:  Lupus       Date:  2016-04-07       Impact factor: 2.911

6.  Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells.

Authors:  T-C Hsu; B-S Tzang; C-N Huang; Y-J Lee; G-Y Liu; M-C Chen; G J Tsay
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

7.  Does parvovirus infection have a role in systemic lupus erythematosus?

Authors:  Tami Hod; Giselle Zandman-Goddard; Pnina Langevitz; Hagit Rudnic; Zehava Grossman; Pnina Rotman-Pikielny; Yair Levy
Journal:  Immunol Res       Date:  2017-04       Impact factor: 4.505

8.  Childhood microscopic polyangiitis associated with MPO-ANCA.

Authors:  Amira Peco-Antic; Branka Bonaci-Nikolic; Gordana Basta-Jovanovic; Mirjana Kostic; Jasmina Markovic-Lipkovski; Milos Nikolic; Brankica Spasojevic
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.651

Review 9.  Glomerular disease in patients with infectious processes developing antineutrophil cytoplasmic antibodies.

Authors:  Konstantin N Konstantinov; Suzanne N Emil; Marc Barry; Susan Kellie; Antonios H Tzamaloukas
Journal:  ISRN Nephrol       Date:  2013-02-19

10.  Antineutrophil cytoplasmic antibody frequency in chronic hepatitis B patients.

Authors:  Turan Calhan; Abdurrahman Sahin; Resul Kahraman; Mustafa Erhan Altunoz; Fatma Ozbakır; Kamil Ozdil; Hacı Mehmet Sokmen
Journal:  Dis Markers       Date:  2014-08-05       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.